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The emergence of bacterial resistance to antibacterial agents continues to be an important clinical problem, although it is 
not shared equally by all bacterial species and classes of antibacterial agent. Gram-negative bacteria exhibit numerous 
drug resistance mechanisms, such as plasmid or chromosomally-mediated P-lactamases, outer membrane permeability 
changes that confer resistance to p-lactams and other drugs and enzymes capable of modifying non-P-lactam drugs, such 
as the aminoglycosides. This has led to increased resistance among Enterobacteriaceae such as Escherichia coli and 
Klebsiella pneumoniae as well as Enterobacter spp. and among glucose non-fermentative Gram-negative bacilli, such as 
Pseudomonas spp., Acinetobacter spp., Burkholderia spp. and Stenotrophomonas maltophilia. Recent years have seen 
Gram-positive bacteria re-emerging as important nosocomial pathogens. Current resistance problems among Gram- 
positive species include methicillin resistance in staphylococci, penicillin resistance in pneumococci and vancomycin 
resistance in enterococci. Some organisms have acquired multiple drug resistance mechanisms making them virtually 
untreatable with contemporary antibacterial agents. Determination of current resistance patterns and the most appropriate 
empirical antibacterial treatment is best achieved by bacterial surveillance. This can be done in individual hospitals, 
nationally between hospitals and internationally between countries. Microbiological surveillance provides vital information 
on the pathogens isolated from patients, particular hospital environments, and other sources, together with common 
patterns of antibacterial susceptibility. Surveillance is likely to be of greatest benefit in environments such as intensive care 
units (ICUs), where patients are at a particular risk of acquiring nosocomial infection. Other benefits include the early 
detection of antibacterial resistance in specific bacteria and a reduction in the inappropriate use of antibacterial agents. 
Studies have shown that infection control measures together with microbiological surveillance can significantly reduce 
infection rates and hospital costs. However, currently the collection of bacterial susceptibility data is incomplete and 
comprehensive national and international data are not yet established or the information is not made widely available. 
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INTRODUCTION antibacterial agents [1,2]. At the time of introduction 
of penicillin G in 1941, less than 1% of hospital strains 
Since the introduction of the first antibacterial agent, of Stapyphylococcus duyeuj were resistant, BY 1946, 
the eniergence of resistance has been a recognized resistance had risen to 14% and a year later to 38% 131. 
problem. Moreover, the selection of drug-resistant In  the 195os, penicillin-resistant S .  auyeus was 
organisms in serious nosocomial infections has reported widely, and followiIlg the illtrodL1ction of 
generally been related to the widespread use of p-lactamase stable penicillins, methicillin-resistant 
staphylococci were reported as carly as 1961 [4]. 
Resistant Gram-negative bacilli emergcd in the 1970s, 
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pneumoniae and Escherichia coli producing plasmid- 
mediated extended-spectrum P-lactamases (ESBLs), 
were first described in Germany in 1983 [5] and now 
occur in many hospitals world-wide [6], particularly 
in ICUs [7]. Recent years have seen the re-emergence 
of Gram-positive bacteria as the most important 
pathogens in community- and hospital-acquired 
infections [8]. Furthermore, multi-resistance among 
Gram-positive genera is increasing globally, 
particularly in pathogens such as penicillin-resistant 
pneumococci [9], methicillin-resistant S .  aureus (MRSA) 
[8] and ampicillin-resistant enterococci that are now 
resistant to glycopeptides [8,10,11]. 
Aminoglycoside resistance has evolved by several 
mechanisms: reduced ribosomal binding, reduced 
uptake and the production of various modifying 
enzymes capable of phosphorylating, adenylating or 
acetylating these agents (APH, ANT, AAC). However, 
permeability mutants limiting drug access to intracellular 
targets sites, particularly among Pseudomonas aeruginosa, 
are becoming prevalent mechanisms of aminoglycoside 
resistance [12,13]. Surveillance studies in some countries 
have demonstrated modest increases in aminoglycoside 
resistance among P. aeruginosa, Enterobacter spp. or 
Citrobacter spp. over time, despite acceptable infection 
control practices [12]. 
The new fluoroquinolones have been in clinical use 
for nearly 10 years. However, resistance has developed 
and is increasing, particularly among P. ueruginosa and 
staphylococci, but has also been reported in E. coli, 
K. pneumoniae, Serratia spp. and Acinetobacter spp. 
Two mechanisms of resistance have been described; 
mutation of the subunit of the enzyme DNA gyrase 
or alteration of the porins [13]. Efflux is also 
an important mechanism of resistance for S. aureus 
The glycopeptides are large, complex 
antibacterials of which only two are in current use, 
vancomycin, introduced in the late 1950s, and 
teicoplanin introduced in the late 1980s. Their use has 
increased recently as bacteria develop resistance to 
other antibacterial agents and with the resurgence of 
Gram-positive pathogens. Resistance to both has 
occurred among enterococci and coagulase-negative 
staphylococci [8,9]. 
The widespread and sometimes indiscriminate or 
suboptimal use of antibacterial agents has led to the 
development of multiple drug-resistance mechanisms, 
such as isoniazid and rifampicin-resistant Mycobacterium 
tuberculosis [16] and glycopeptide-resistant enterococci. 
These organisms are resistant to almost all currently 
used antibacterial agents making them extremely 
difficult to treat. 
~ 4 1 .  
SURVEILLANCE 
In seriously ill patients, particularly neutropenic 
patients and those in the ICU, antibacterial therapy is 
mostly empirical and must be initiated before results of 
microbiological cultures are available. One way of 
selecting the appropriate antibacterial regimen is to 
monitor the local prevalence and distribution of the 
major pathogens and their susceptibility patterns. This 
can be done by surveillance: locally, in individual 
hospitals [16-181; nationally, on a countrywide basis 
[19-211; or internationally, between countries [22,23]. 
The ability to regularly survey prevalent pathogens 
and their resistance patterns enables hospitals to update 
their prescribing policy. To be effective, surveillance 
programmes must use information obtained both 
locally from within the hospital and externally, as 
antibacterial agent resistance patterns may vary. 
Regional and national data can identify general 
antibacterial agent resistance patterns, while local 
hospital information quickly identifies resistance 
within the institution and provides a basis for infection 
control measures. Data on resistance prevalence are 
often under-analyzed and fi-agmentary, and need to be 
generated from medical microbiology laboratories 
with reproducible methodology [2]. International 
studies have the added problem that they may only 
include a single hospital from individual countries and 
this may not reflect true resistance patterns. 
Surveillance data that adjust for specific infection risks, 
such as those associated with specific sites, devices, 
ICUs, surgical wound infections and other at-risk 
populations, may provide better inter-hospital 
comparisons. 
In 1978, the World Health Organisation (WHO) 
recommended surveillance as a tool to provide current 
susceptibility data in order to monitor antibacterial 
resistance [24]. Currently, national or global 
prospective surveillance systems for monitoring 
antibacterial resistance as well as national and 
international susceptibility data are unsatisfactory and 
should be improved [25]. 
In the United States, various formalized systems for 
ongoing national surveillance provide systematic 
information concerning infection rates and the relative 
importance of pathogens. The Centers for Disease 
Control (CDC) and prevention has a system called the 
National Nosocomial Infection Surveillance (NNIS) 
which monitors serious infections in hospitalized patients 
from medical centers throughout the USA [21]. 
The American Society of Microbiology (ASM) is 
concerned about the national and global increase in 
antibacterial resistance [26,27], It convened the Task 
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Force on Antibiotic Resistance comprising scientists 
from academic, government and industrial sectors to 
consider the current prevalence of antibacterial 
resistance, major factors affecting the emergence of 
antibacterial resistance, major research needs and 
future surveillance strategies for monitoring resistance. 
Their recommendations were that a national surveillance 
system should be established immediately [26,27]. 
In Europe, no  such active surveillance system 
exists and there have been few studies of nosocomial 
infections, particularly in the I C U  environment. 
However, a recent international study, the European 
Prevalence of Infection in Intensive Care (EPIIC), was 
undertaken to measure the incidence of infection in 
ICUs of 17 countries in Western Europe isolated on a 
single day in 1992 [28]. EPIIC is the largest point 
prevalence study of infection in ICUs and involved a 
total of 10,038 patients. O f  these patients, 45% had 
infections, with almost half (45.9%) of these originating 
in the ICU. The susceptibility of the isolates was 
determined using routine, though standardized 
methodology, as recommended within the individual 
countries. 
In 1975, the Paul Ehrlich Society began a study to 
examine the development of bacterial resistance in 
central Europe [29]. Data were collected from 
multicenter studies in Germany, Austria and Switzerland 
using identical methods and control systems. Australia 
also established a national surveillance program in 
1993 [30]. 
In less developed countries, surveillance of 
antibacterial resistance is often more problematic. 
Most of the conditions that encourage antibacterial 
resistance development, such as self-medication, over- 
the-counter sales, high patient:health care worker 
ratio, overcrowding of hospitals, poor infection 
control policies, and scarce documentation are present 
in countries such as Central and South America, 
Africa and Asia [13,31-331. Ease of travel has 
potentiated the spread of resistant microorganisms 
around the world. The WHO has been active in 
promoting the rational use of drugs in developing 
countries and monitoring the emergence of resistant 
organisms [34]. It has implemented an international 
program of antibacterial resistance surveillance, called 
WHONET,  with the participation of 121 laboratories 
from 41 countries around the world. 
Methodological differences 
The problems of antibacterial resistance are ofEen difficult 
to assess, as susceptibility tests with their different 
interpretations, standardization and breakpoints vary 
&om country to country, making comparisons difficult. 
Moreover, the detection of certain types of resistance, 
such as the chromosomally-mediated p-lactamases and 
the extended spectrum P-lactamases, should rely upon 
precise guidelines (eg. synergy between third-generation 
cephalosporins and clavulanate) and should be performed 
routinely, as susceptibility patterns of various p-lactams 
can vary significantly. 
Ideally, a single standardized, quantitative and 
reference quality method should be used to provide 
comparative data for the various countries around the 
world. A number of molecular biology techniques can 
be applied to confirm the identification of pathogens 
and detect outbreaks and resistant clones among 
nosocomial isolates. These include restriction enzyme 
analysis of genomic DNA, plasrnid profiling with and 
without restriction enzyme analysis, ribosomal R N A  
probing of restricted genomic DNA, DNA sequencing 
of the target pathogens, pulsed field gel electrophoresis 
and the polymerase chain reaction (PCR). These 
techniques may become an essential component in 
detecting multiply resistant organisms, as part of the 
infection control [35]. 
In addition, interpretation of resistance data should 
take into account some crucial epidemiologcal aspects 
of the studies, such as whether repeat isolates are 
excluded or not [36], the type of ward, the type of 
patients included, whether the infection is nosocomial- 
or community-acquired [37] and the time of acquisition 
of the infection [38]. 
EPIDEMIOLOGY OF RESISTANCE 
Over recent years, changes in the distribution of 
organisms and drug resistance patterns have emerged 
among nosocomial pathogens [39]. The five most 
commonly reported nosocomial pathogens in the 
NNIS study (1 989-1 992) were coagulase-negative 
staphylococci (CNS), E. coli, S. aureus, enterococci and 
P. aeruginosa [21]. In the ICU, infections are typically 
caused by pathogens that are different to those found 
in general hospital wards and are often more refractory 
to antibacterial treatment [40]. The most predominant 
pathogens include P. aeruginosa, S.  aureus, CNS, Candida 
spp., Enterobacter spp., enterococci, E. coli, Acinetobacter 
spp., Klebsiella spp. and streptococci [21,28,41]. A study 
conducted in 1990 between four European countries 
and the USA, found the most prevalent species isolated 
in the ICU to be: P. aeruginosa, E.  coli, Klebsiella spp., 
Acinetobacter spp., P. mirabilis, Enterobacter spp. and 
Serratia spp. [38]. The epidemiology of severe infections 
in the ICU is covered in detail by Wolff et al. [41]. 
One of the most alarming changes over the last 10-15 
years has been the gradual increase of resistant pathogens 
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causing serious nosocomial infections. However, 
McGowan et al. found that the prevalence of resistance 
among hospital pathogens is largely due to differences 
between the distribution of organisms responsible for 
nosocomial infections, compared to those responsible 
for community-acquired cases. In contrast, hospital 
isolates of a given organism were more resistant than 
the community-acquired isolates of the same organism 
for only some organism and drug combinations 1371. 
Several multi-resistant Gram-negative organisms 
are being encountered with increasing frequency in 
hospitals and are likely to establish themselves as 
serious causes of infection [42,43]. Concern has been 
expressed over the increased frequency of Acinetobacter 
infections in hospitalized patients particularly in cases 
of nosocomial pneumonia [38]. In a study conducted in 
39 French ICUs in 1991, Acinetobacter spp. was the third 
most prevalent Gram-negative pathogen, accounting for 
approximately 10% of all aerobic Gram-negative isolates 
[38]. Recently S. rnaltophilia has become a significant 
pathogen [44]. In the French study, S. rnaltophilia 
accounted for 1.9% of Gram-negative isolates in the 
I C U  [38]. Furthermore, over the last decade 
Burkholderia cepacia has become a major threat to 
patients with cystic fibrosis [44]. To  complicate the 
problem, antibacterial resistance, long considered the 
domain of Gram-negative bacteria, is being increasingly 
exhibited by Gram-positive strains [8]. 
The major mechanisms of resistance among Gram- 
positive and Gram-negative bacteria to p-lactams, 
aminoglycosides and fluoroquinolones are listed in 
Tables 1-3 [45]. 
The incidence of resistance among nosocomial 
pathogens to parenteral antibacterial agents has been 
studied in a surveillance study conducted in the US in 
1994 [46]. Gram-positive and Gram-negative organisms 
isolated from 43 medical centers, using National 
Committee for Clinical Laboratory Standards (NCCLS) 
methodology, were collected (Table 4). Another large 
surveillance study conducted in the US examined 
resistance rates among 33,869 Gram-negative bacilli 
collected from 396 ICUs between 1990-1993 [47]. 
The main trends in antibacterial resistance are 
discussed in detail below. 
Staphylococci 
S.  aureus is causing continual concern in hospital 
infections due to the emergence of increasingly resistant 
strains, with high epidemic potential and virulence. 
Today, more than 90% of strains of S. aureus have 
been reported as resistant to penicillin by P-lactamase 
production [8]. These resistant strains are usually 
susceptible to oxacillin, the isoxazoyl penicillins, 
methicillin, most cephalosporins and p-lactam/ 
p-lactamase inhibitor combinations. 
Oxacillin (methicil1in)-resistant strains with an 
additional, altered penicillin-binding protein (PBP) 
(PBP-2A) are increasing in frequency, and are resistant 
to all p-lactam compounds [8,48]. Today MRSA is a 
major nosocomial pathogen found throughout the 
world, and associated with an increasing number of 
hospital infections [48-501. 
In the USA, the percentage of MRSA among all 
S .  aureus isolates from NNIS hospitals increased from 
2.4% in 1986 to 29% in 1991 [21]. An even greater 
problem exists in Japan where MRSA isolates accounted 
for 60% of all S.  aureus strains [51]. In the EPIIC 
study, 60% of isolates were methicillin-resistant, with 
the highest incidence occurring in Italy and France, 
although some European hospitals reported no cases 
caused by MRSA [28]. In another Pan-European study 
published in 1994, 43 laboratories from 10 countries 
screened a total of 7,333 consecutive isolates for 
methican-resistance. Overall the proportion of MKSA 
was 12.8% with a range of < 1% in Scandinavia to 
> 30% in Spain, France and Italy [52]. 
Al though initially susceptible to  the 
fluoroquinolones, many strains of staphylococci now 
show high levels of resistance. Indeed, the overall rate 
of resistance to ciprofloxacin among S .  aureus isolated 
in the NNIS study (1989-1992) was 2796, although 
resistance among MKSA to ciprofloxacin was as high 
as 80% [ 5 3 ] .  In a large study involving 78 laboratories 
&om 12 European countries, the overall rate of resistance 
to ciprofloxacin among staphylococci was higher among 
oxacillin-resistant S .  aureus (70.6%) and oxacillin- 
resistant CNS (51.2%) compared to oxacillin-sensitive 
S. aureus (6.5%) and oxacillin-sensitive CNS (15.9%) 
154). Although there is no serious evidence of 
vancomycin resistance in S .  aureus, strains with reduced 
susceptibility to teicoplanin have been reported in 
France [55; Mainardi: personal communication]. In a 
more recent survey, (the European collaborative 
study), 70 laboratories from nine countries examined 
the susceptibility of Gram-positive cocci to the 
glycopeptides, using NCCLS criteria. Out of a total of 
2,852 strains, no S. aureus isolates were resistant to 
either teicoplanin or vancomycin [56]. 
Among CNS in the EPIIC study, 70% were 
resistant to methicillin and 66% resistant to gentamicin. 
Pooled data (1990-1992) from the NNIS indicated 
that > 50% of CNS were methicillin-resistant in the 
USA [21]. A high incidence of MRSA and 
methicillin-resistant CNS has also been reported in 
hospitals in Australia, Africa, south-east Asia, China 
and South America [30,49,50]. 
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Table 1 Resistance mechanisms for p-lactam antibiotics (penicillins, cephalosporins, monobactanis, carbapenems) used to 
treat severe infections, data adapted from Neu [45] 
Antimicrobials Mechanisms Genetic basis Crisis now Future cnsis 
p-lactanis Altered penicillin binding proteins Chromosomal 
Reduced permeability Chromosomal 
S .  pneumoniae N. meniqitidis 
S. epidermidis 
S. aureus 
P. aeniginosa 
E.  cloacae 
S .  marcexens 
K. pneumoniae 
p-lactamase Plasmid or chromosomal Stenotrophomonas Hncteroides spp. 
Acinctobacter spp. N. meningitidis 
Enterobacteriaceae Enterococci 
Table 2 Resistance mechanisms for fluoroquinolones (norfloxacin, ofloxacin, ciprofloxacin, lomefloxacin) used to treat 
tevere infections, data adapted from Neu [45] 
Antiniicrobials Mechanisms Genetic basis Crisis now Future crisis 
Fluoroqumolones Altered DNA gyrase 
Rcduced permeability 
Chromosomal 
Chromosomal 
MRSA EnterobaLtenaceae 
Pseudomonas Haemophilu~ spp 
S pneumoniae N Xonorrheoae 
Swaf ia  spp Entcrobactenaceae 
P aerupzosa 
Modification of topoisomerase IV P l a m ~ d  S .  pnenmoniae 
S. auwuc 
Emux Chromosomal S. aure~is 
Table 3 Resistance mechanisms for aminoglycosides (gentamicin, amikacin, tobramycin) used to treat severe infections, 
data adapted from Neu [4S] 
Antiniicrobials Mechanisms Genetic basis Crisis now Future Crisis 
Aminoglycosides Decreased ribosomal binding Chromosomal 
Keduced uptake Chro~nosotnal 
Modifying enzynies Plasmid 
Streptococci 
Pseudomonas Enterobacteriaceae 
Enterococci Streptococci 
Pseudomonas 
Enterobacteriaceae 
Resistance to glycopeptides, is somewhat more 
common among CNS, especially S .  kacrnolyticus. Such 
strains have been reported from France, Germany, Spain, 
UK and the USA [56]. In the European Collaborative 
Study, out of a total of 1,444 CNS, 0.6% were resistant 
to teicoplanin and 0.1% were resistant to vancomycin 
[SO]. Other studies have reported teicoplanin resistance 
(MIC 2 32 nig/L) in 1.7-3.2% of all CNS species [57]. 
Enterococci 
Enterococci are a major cause of hospital-acquired 
infections and are a common cause of nosocomial 
morbidity and mortality, although there is some 
controversy regarding their virulence. They possess 
low affinity PBPs and are generally regarded as resistant 
to cephalosporins [8], and demonstrate a remarkable 
ability to acquire new resistance determinants [SS ] .  
Several recent problems have made the treatment of 
infect ions caused b y  Enterococcus spp.  difficult: 
P-lactamase production (rare < 1 %I); chromosomally- 
mediated alterations in PBPs (frequent and > 20% 
overall); and  plasmid-mediated aniinoglycoside 
inactivating enzyme production (up to  50%), which 
confers high level resistance. High level resistance to 
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Table 4 Baseline antimicrobial resistance patterns reported in 43 centers in the US from 1993-1994, data selected from 
Jones et al. [46]. With permission of Elsevier Science 
Resistant organism Percent resistant Average Method adjusted ratea 
Penicillin-resistant Streptococcus pneumuniae 1-30 7.9 17.8 
Ampicillin-resistant enterococci 
Enterococcus faecillis 1-3 1.7 
Enterococcus faecium 20-82 56.9 
Group 1 cephalosporinase resistance" 
Citrobacferjeundii 2-60 28.4 
Enterobacter cloacae 5-58 31.0 
Pseudomonas aeruginosa 2-28 12.2 
Escherichia coli 1-39 5.4 
Klebsiella spp. 1-58 7.1 
Extended-spectrum P-lactamaseb 
Imipenein resistance 
Enterobacter spp. 1-9 4.0 
Movanella movganiic 9-46 20.8 
Proteus mirabilisc 3-34 17.9 
Serratia marcescens 1-13 5.2 
Stenotrophomonas maltophilia 84-100 93.0 
Pseudomonas aeruginosa 4-24 11.2 
Vancomycin resistance 
coagulase-negative staphylococci 1 -3 1.5 
Enterococci 
Enterococcus faecalis 0.2-22 5.2 
Enterococcus faecium 1-42 15.6 
Fluoroquinolone resistanced 
Staphylococcus aureus 
oxacillin-resistant 3-100 64.3 
oxacillin-susceptible 1-84 17.1 
oxacillin-resistant 4-9 1 51.3 
oxacillin-susceptible 3-90 23.2 
Enterobacter spp, 1-33 6.6 
Escherichia coli 0.2-27 2.6 0.8 
Klebsiella spp. 1-32 6.3 
Serratia spp, 3-39 14.1 6.8 
Pseudomonas aeruginosa 5-90 18.1 14.9 
Pseudomonas spp. 8-7 5 34.1 
Stenotrophomonas maltophilia 14-100 45.0 
coagulase-negative staphylococci 
Citrobacferjeundii 1-24 8.0 9.9 
aRate observed when using more accurate E test System (AB Biodisk, Solna, Sweden). 
"Based on ceftazidime resistance rate. 
CThese species only moderately susceptible to inipenein. 
dBased on ciprofloxacin resistance rate. 
streptomycin in Enterococcus spp. is due to the 
production of ANT-6, whereas high-level resistance 
to the other aminoglycosides, including gentamicin, is 
due to the dual production of AAC (6') plus APH (2') 
or APH (3'). Among nearly 2,000 enterococci isolated 
from 97 centers in the USA in 1992, 27% and 36% 
showed high level resistance to gentamicin and 
streptomycin, respectively. 
More recently, resistance to vancomycin has 
evolved and is mediated by an altered D-alanyl-D- 
0.5 
9.7 
7.9 (all species) 
24.9 (all strains) 
alanine pentapeptide terminus [59], making infections 
with vancomycin-resistant strains essentially untreatable. 
Vancornycin resistance is more common in E. faecium 
than E. faecalir. There are four resistance phenotypes, 
Van A-D, although VanA and VanB are the most 
prevalent. Those of the VanA phenotype are also 
resistant to teicoplanin, but VanB and VanC strains 
remain teicoplanin-susceptible. 
Strains of glycopeptide-resistant enterococci have 
been found in many parts of the world, including 
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Belgium, France, Germany, Italy, Netherlands, Spain, 
UK and the USA [56,59]. There is evidence that the 
number of hospitals affected by such resistant 
organisms has increased in recent years, as reported 
fiom the UK [59] and the USA [%I. Out  of a total of 
nearly 2,000 enterococci isolated from 97 centers in 
the USA in  1992, 23% of centers reported 
vancomycin-resistant strains, accounting for 4.4% of 
the total number of isolates. In 1994, this had risen to 
61% of centers [58]. Teicoplanin remained active in 
vitro against 28% of vanconiycin-resistant enterococci 
(VanB phenotype). An increase in glycopeptide- 
resistant enterococci was noted particularly in ICUs, 
in which the proportion of resistant isolates increased 
from 0.4% in 1989 to 13.6% in 1993. In the European 
Collaborative Study, 1.7% of strains overall were 
resistant to teicoplanin and 2.3% were resistant to 
vancomycin [56]. 
Some of the older drugs, chloramphenicol, 
novobiocin and doxycycline, remain active against many 
multiresistant enterococci although there is no generally 
accepted approach to the therapy of enterococcal 
infection due to strains resistant to penicillins, 
aminoglycosides and glycopeptides [57]. 
Pneumococci 
Penicillin resistance in pneumococci has risen 
dramatically over the last 25 years and is now a global 
problem. Resistance is mediated by alterations in 
PBPs and is described in more detail by Klugman et al. 
in this supplement [60]. In addition to high levels of 
resistance to p-lactams, many strains exhibit multiple 
resistance to trimethopnm/sulfamethoxazole, macrolides, 
tetracyclines and chloramphenicol [60,61]. 
Penicdhn resistance rates (intermediate and resistant) 
of between 25-70% have been recorded in many 
countries including Spain, Hungary, Israel, Chile, New 
Guinea, France and South Africa [60]. 'The incidence 
of penicillin-resistant strains in the UK and Australia is 
relatively low in comparison [61,62]. A recent 
surveillance study conducted by Public Health 
Laboratories in the UK (PHLS) monitored penicillin 
resistance amongst pneumococci, and noted an increase 
from 0.3% in 1989 to 2.5% in 1994 [62]. In the USA, 
the C D C  reported only a 5% resistance rate between 
1979-1987 [39], with an increase to 18% in 1994, with 
a range of 1-30% [52]. In 1995, the rate was found to 
be 27.2% in a 24-medical-center study m d  23.6% in a 
30-center study, both conducted in 19'35 [63,64]. 
Escherichia colifKlebsiella species 
The novel extended-spectrum p-lactamases (ESBLs; 
mostly derivatives of TEM-1, TEM-2 and SHV-1) are 
of concern. They are increasing among Klebsiella spp. 
and other Enterobactenaceae such as E.  coli, particularly 
in teaching hospitals and ICUs [65,66]. Many of these 
strains are multi-resistant to many p-lactams and some 
non p-lactam antibacterials. 
NNIS data for the USA in 1987-1991 indicated that 
the percentage of ceftazidime-resistant Klebsiella spp. 
increased from 1.5% to 3.6%, and in one hospital the 
incidence was as high as 39% [67]. In another study 
conducted among 396 ICUs in the USA [47], the 
incidence of ceftazidime resistance among K.  pneumoniae 
rose from 3.6% in 1990 to 14.4% in 1993 (p 5 0.01). 
Resistance rates among Klebsiella isolates to ceftazidime 
from ICU patients have been reported to be 16% in 
France, 11% in the UK, 20% in Latin America and as 
high as 50% in Bangkok [13,65]. 
In another European study conducted in 1990, 
resistance to ceftazidime among K.  pneumoniae waF 36% 
in France, 13% in Belgium and 12% in the Netherlands 
[38]. In a further study conducted in ICUs in Western 
and Southern Europe, the incidence of ESBL among 
Klebsiella spp. was up to 49% in Portugal and 59% in 
Turkey [7]. Furthermore, the vast majority of ESBL 
isolates also have associated resistance to gentamicin and 
other aminoglycosides [13]. In two of these studies 
associated resistance to ciprofloxacin was common in 
certain hospitals in France [7,38]. Fluoroquinolone 
resistance among E.  coli (28%) and Klebsiella spp. (8%) 
has also been reported among patients with bacteremia 
and cancer. This has been attributed to the widespread 
prophylactic use of these agents in this population, and 
to multiclonal emergence of resistant mutants [68,69]. 
Other Enterobacteriaceae 
Overproduction of chromosomally-mediated Bush 
group 1 cephalosporinases from Enterobacteriaceae 
confers resistance to almost all p-lactams (including 
third-generation cephalosporins and p-lactam/ 
P-lactamase-inhibitor combinations) except the 
carbapenems. Most strains are still susceptible to the 
fourth-generation cephalosporins (cefpirome and 
cefepime). This resistance is conferred by the AmpC 
gene and is characteristic of Enterobacter, Citrobacter, 
Sewutia and indole-positive Protetrs spp. Most resistance 
in Enterobacter spp. is a result of selection of pre- 
existing mutant organisms that produce large amounts 
of 0-Iactamase constitutively. Resistance rates against 
ceftazidime of up to 56% have been reported and 
these are increasing [65,70]. Indeed, the NNIS data 
for 1987-1991 indicate an increase to 38.6% in the 
USA [60]. High levels of resistance among 
Enterobacteriaceae (10-48%) have also been observed 
in Europe, Latin-America and Japan [30,70]. AmpC 
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genes have also been found on transferable plasmids in 
E. coli and K. yneumoniae on a worldwide scale, leading 
to resistance to cephalosporins, including cephamycins 
(e.g. cetoxitin) [71]. 
Ceftazidime-resistant Enterobacter spp. often have 
associated resistance to other antibacterial classes such as 
the aminoglycosides and the fluoroquinolones. The most 
prevalent aminoglycoside resistance mechanism among 
Enterobacteriaceae is the production of inactivating 
enzymes; AAC (3)-V, AAC (6'-1) and APH (30-VIII) 
1131. High level aminoglycoside resistance among 
Enterobactenaceae may be in part plasmid-mediated and 
thus has the potential to be disseminated further [72]. In 
a surveillance study conducted in the USA between 1990 
and 1993, 7% of 5,451 isolates were resistant to 
gentamicin and tobramycin. In Latin America, 
aminoglycoside resistance is a more serious problem with 
> 40% of E. cloacae strains resistant to gentamicin and 
tobramycin [13]. In 1990, the overall rate ofresistance to 
fluoroquinolones among Enterobacteriaceae in Europe 
was 1.8% [54]. Resistance rates among Entero- 
bacteriaceae that were above 5% were S. marcescens 
(9.9%), S. liquefacienr (7.5%), Enterobacter aerogenes (1 1.4%) 
and Providencia stuartii (26.7%). 
Pseudomonas aeruginosa 
Resistance among P. aeruginosa isolates to p-lactams can 
be enzyme-mediated, including both chromosomally 
and plasmid-mediated P-lactamases. More recently, 
resistance to imipenem has emerged and is attributed 
to both the loss of an outer membrane porin protein 
(predominant mechanism) and a currently rare 
plasmid-encoded imipenemase 173,741. 
From the NNIS data, the incidence of cefiazidime 
resistance among P. aeruginosa isolates had not risen 
between 1987-1991 (10% and 9%), however, there 
was 11% resistance to imipenem among > 4,000 
isolates [21]. Resistance was primarily seen in isolates 
of patients with respiratory tract infections admitted to 
teaching hospitals. An increase in resistance to 
imipenem (0-40%) in P. aeruginosa was also reported 
in specific ICUs from 1988 to 1992 1751. 
In the EPIIC study, 46% of P. aeruginosa isolated in 
the ICU were resistant to gentamicin, 28% were 
resistant to ceftazidime and 21% were resistant to 
imipenem, with the highest levels of resistance occurring 
in Greece, Italy, Spain and France. In the UK over the 
last eight years test results from 61 laboratories have 
been collected in a national computerized database, 
with data on 1.7 million strains. Though no attempt 
has been made to assess the quality of these data, each 
laboratory participated in external quality assurance 
schemes and used documented methodologes. Between 
1986 and 1993, there was no change in the susceptibility 
pattern of P. aemginosa to cefiazidime, imipenem and 
piperacillin (Table 5) [76]. 
Prior to their introduction in 1986, all the 
P .  aeruginosa  isolates were susceptible to the  
fluoroquinolones. Resistance has now developed, with 
10% of strains being resistant to ciprofloxacin by 1993. 
A similar level of resistance has also been recorded in 
other areas of the world including the USA [42,68]. 
In the NNIS survey, ciprofloxacin resistance among 
P. aeruginosa isolates from the respiratory tract rose 
from 2.0% in 1989-1990 to 5.3% in 1991-1992. In a 
more recent nationwide survey conducted in the 
USA, resistance was estimated at 18% 1411. In Europe 
the overall rate of ciprofloxacin resistance among 
P. aemginosa isolated from 12 countries was 13% 1541. 
The incidence of aminoglycoside resistance among 
P. aemginosa is especially high in certain Latin-American 
countries, where gentamicin resistance is well over 
40% and amikacin resistance varies from 13-24% [13]. 
Resistance was attributed to the production of 
inactivating enzymes, mainly AAC (3)-V and AAC (3)-I 
but 3048% of isolates were resistant by impermeabdity. 
Table 5 P. aeruginosa susceptibility in the UK, 1986-1996, data selected from Spencer 1761 
Compound % susceptible (number of strains tested) 
1986 1993 
Gentamicin 94 92 
Imipenem ND 89 
CeEtazidime 97 96 
Ciprofloxacin 100 90 
(1939) (1709) 
(757) 
(1 308) (1664) 
(8) (1559) 
Piperacillin 93 93 
(1458) (957) 
ND = No data 
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Other non-fermentative Gram-negative bacilli 
Numerous reports have documented the high rates of 
antibacterial resistance found in Acirzetobacter spp. A 
particular concern has been the frequency of multiple 
resistance exhibited by nosocomial Acinetobacter spp. and 
the resulting therapeutic problems involved in treating 
patients with nosocomial infections in the ICU [77]. 
Most strains are resistant to aminoglycosides but some 
remain susceptible to third- and fourth-generation 
cephalosporins, imipenem and fluoroquinolones. 
Cephalosporin resistance i s  mainly associated with 
chromosomally-mediated cephalosporinases, often in 
conjunction with permeability reduction and altered 
PUPS [77]. A potentially worrying development is the 
occurrence of a novel p-lactainase (ARI-l), in an 
imipenem-resistant strain of A. baurnannii. Ths enzyme 
hydrolyzes imipenem and azlocillin but not the 
cephalosporins. Moreover, there are recent reports of 
hospital outbreaks which have documented the spread 
of imipenem-resistant strains [78]. 
S. rnaltopkilia is commonly resistant to many 
antibacterial agents including most antipseudomonal 
p-lactams and aminoglycosides. Therefore treatment 
of infections caused by this pathogen can be difficult 
[44,79]. The main enzymatic mechanism of resistance 
is the production of zinc-metallo carbapenemase 
which confers high levels of resistance to imipenem, 
meropenem and other p-lactam compounds. 
Mechanically ventilated patients, receiving antibacterial 
agents (particularly carbapenems), are at  increased risk 
of becoming colonized or  infected with this 
organism. 
B. ceparia is resistant to a wide range of antibacterial 
agents including polymyxin, aminoglycosides, some 
fluoroquinolones and the antipseudomonal penicillins. 
Other p-lactams such as some third- and fourth- 
generation cephalosporins, temocillin, imipenem, 
sulbactain, fosfomycin and ciprofloxacin display 
some activity against this organism, although there is 
evidence that some strains produce a carbapenemase 
[44,80]. 
IMPLICATIONS OF SUSCEPTIBILITY CHANGES ON 
THERAPEUTIC CHOICE 
When a serious nosocomial infection is suspected, 
treatment must be commenced immediately to increase 
the likelihood of a satisfactory outcome. As described 
previously, the choice of the most appropriate 
antibacterial agent for empirical treatment should be 
guided by the information generated from recent local 
Furveillance. When both Gram-negative and Gram- 
positive organisms are implicated, a broad-spectrum 
antibiotic or combination of more narrow-spectrum 
antibiotics can be selected as the choice of empirical 
therapy. 
Emerging resistance problems limit the utility of 
currently available antibacterial agents (271. Problems 
with resistance to penicillins led to cephalosporins 
becoming the preferred p-lactams. Although the 
third-generation cephalosporins have broad-spectrum 
activity they have deficiencies in their antibacterial 
spectrum. Ceftazidime has the greatest spectrum of 
activity among the third-generation cephalosporins 
against Gram-negative organisms and is used 
frequently in the treatment of serious infections. 
However, it lacks consistent activity against 
G r a m - p o s i t iv e in  o s t i nip o r t a n t 1 y 
staph y 1 o c o c c i . four th  - g e n e r a t i o n  
cephalosporins (Le. cefpirome and cefepime) and the 
carbapenenis (imipenem and meropenem) both have 
broad-spectrum activity which includes most Gram- 
negative and Gram-positive organisms that cause 
serious infections in the ICXJ, including most 
Enterobacteriaceae, P. aevuginosa and methicillin- 
susceptible staphylococci. 
A number of surveillance studies conducted in the 
USA and Europe have examined current susceptibility 
patterns of nosocomial isolates to a range of broad- 
spectrum antibacterial agents. One  large study 
examined the susceptibility of a total of 41,000 clinical 
isolates to 22 antibacterial agents (at least 5,000 isolates 
per compound) isolated in 236 medical centers, using 
standardized disk diffusion tests [81]. The drugs were 
ranked in order of activity against the total number of 
pathogens (Table 6). Overall, piperacillin-tazobactam 
and imipenem were the most often active, inhibiting 
> 90% of isolates, followed by ofloxacin (87')/0), 
ciprofloxacin (82%) and cefiazidime (75.5%). Another 
study reevaluated a further 5,000 strains, after 5 years, 
isolated from five medical centers and included the 
fourth-generation cephalosporin cefepime [82] .  
Imipenem and piperacillin-tazobactarn had > 90% 
inhibition of all isolates followed by the fourth- 
generation cephalosponn (> 85%). All the other drugs 
had <: 79.4% inhibition (Table 6). The overall 
susceptibility to some fluoroquinolones was lower in 
this study than one previously reported by Murray et 
al. [83] (91%). In a further study of8,500 Gram-positive 
and Gram-negative hospital isolates conducted in the 
USA, 83.4% were susceptible to ofloxacin and 82% to 
ciprofloxacin, respectively [46]. 
In a European study conducted in 1990 [84], the 
epidemiology and susceptibility of 8,625 ICU and 
hematology bacterial isolates were determined to third- 
and fourth-generation cephalosporins and imipenem 
pathogens , 
T h e  n e w 
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Table 6 Ranked overall susceptibility (“h) of parenteral antimicrobial agents tested against > 5,000 aerobic isolates (Gram- 
positive and  Gram-negative) from the  US (1989-94), data adapted &om Baron  et al. and  Marshall et al. [81,82] 
Antimicrobial agent 1989a 1994b 
Piperacillin-tazobactam 
Imipenem 
Cefepime 
Ofloxacin 
Cefiazidime 
Gentamicin 
Ticarcillin-clavulanate 
Ceftriaxone/cefotaxime 
Ampicillin-sulbactam 
Piperacillin 
Ticarcillin 
Ampicillin 
92 
93.6 
N T  
87 
75.5 
77 
73.3 
72 
N T  
NT 
N T  
NT 
93.5 
93.5 
86.7 
N T  
79.4 
NT 
74.5 
74 
72.6 
61 
44.5 
33.3 
~~~ 
aRepresents data &om 5,889 strains interpreted by current NCCLS (1994) cntena 
bRepresents data from 5,039 strains interpreted by current NCCLS cntena 
N T  = Not tested 
using NCCLS methodology. Ce@irome and imipenem 
exhibited the least resistance, followed by cefotaxime, 
ceftazidime and ceftriaxone. The study showed that 
> 83% of all isolates were susceptible to imipenem and 
cefpirome and 70% were susceptible to ceftazidime. 
Cefpirome and imipenem were also the most active 
agents against organisms resistant to ceftazidime (Table 7) 
[85]. These results are in agreement with a US study, 
where the activity of cefpirome was compared with all 
the clinically available third-generation cephalosporins 
against nearly 6,000 recent clinical isolates from 
five medical centers, using standardized NCCLS 
methodology [86]. 
All these studies indicate that the new fourth- 
generation cephalosporins, the carbapenems and 
piperacillin-tazobactam have broad-spectrum activity 
and are likely to encounter few resistant strains at present. 
STRATEGIES TO REDUCE RESISTANCE DEVELOPMENT 
The use of antibacterial agents can exert a selective 
pressure that favors the emergence of drug-resistant 
organisms which then accumulate in the hospital 
environment. Improved infection control policies should 
minimize this problem. The ASM has recommended 
that a number of issues should be addressed such as 
reducing the overprescribing of antibacterials and 
resulting resistance selective pressures, reducing or 
modifying the public expectations of the need for 
antibacterials for nonbacterial infections and reducing the 
use of antibacterials in animal food production [26,27]. 
Studies should be initiated to define more 
accurately the risks of drug-use patterns on the 
selection of resistant microbial strains. When usage is 
associated with emerging resistance, interventions at 
Table 7. Activity of p-lactams against ceftazidime-resistant bacteria, data selected from Spencer [85] 
Organism % sensitive toa 
n Cefpirome Ceftriaxone Imipenem Piperacilhn 
E. cofi 42 69 17 86‘ 29 
Klebsiella spp. 91 47 15 90c 3 
Enterobacter spp. 205 73 7 94 9 
Citrobacter spp. 
Proteus spp. 
P .  aemginosn 
38 92 11 100 13 
28 54 39 79b 46 
213 11 0 66 19 
’Sensitivity based on NCCLS breakpoints. 
bThis species only moderately susceptible to imipenem 
Wncontrolled results 
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local, regional or national levels should be initiated to 
limit the problem. Furthermore, institutions must 
practice proper infection control to prevent the 
horizontal transfer of drug-resistant organisms (mutants 
or plasmid-mediated). Standards for infection control 
in hospitals are needed, as is the use of standardized 
methods that have been validated, quality controlled 
and quality assured [30]. Close adherence to infection 
control policies should reduce the spread of infections 
and (multi-) resistant strains. There is strong evidence 
that strict adherence to infection control procedures 
can prevent nosocomial outbreaks with these organisms. 
It may be possible by switching or cycling 
antibiotics to minimize the selection of drug-resistant 
organisms. A cycling scheme for the arninoglycosides 
has been established [87] and should be evaluated for the 
p-lactams. The widespread use of the third-generation 
cephalosporins has led to the emergence of resistant 
Enterobacteriaceae caused by various p-lactamase- 
resistance mechanisms [27]. Indeed, when ceftazidime 
was used in excess in the hospital environment, a 
resistant subpopulation of cephalosporinase stably 
overproducing mutants was selected [67]. Complete 
removal or diminished use of this compound has 
resulted in a decline in resistance rates [88]. 
In 1996 Sanders et al. proposed a cycling scheme 
for the empirical therapy of Gram-negative infections, 
whereby every two months three p-lactams plus or 
minus an aminoglycoside were cycled [89]. The 
p-lactams suggested were a penicillin plus or minus a 
P-lactamase inhibitor, a fourth-generation cephalosporin 
(cefpirome or cefepime) and a carbapenem. The precise 
drugs used for each cycle should be tailored to fit the 
needs of the unit. For example, if P. aeruginora is a 
problem pathogen for the unit, an antipseudomonal 
penicillin will be preferred for the penicillin phase of 
the cycle while ampicillin may be preferred for units 
with problems with Gram-positive organisms. 
It is important to note that the cycling scheme is 
for empirical therapy only. Once the etiological agent 
of infection has been identified, the patient must be 
switched to another therapy specifically targeted for 
the pathogen isolated. 
A scheme to cycle antibiotics can consist of any 
number of antibiotics, however the effectiveness of 
the cycle depends upon how diligently it is adhered to 
and the appropriateness of the antibacterials chosen for 
the specific site in question. 
As it is very difficult or impossible to predict 
the bacterial resistance that will be evolving, 
microbiological surveillance studies will continue to 
be necessary to detect future trends in antibacterial 
resistance. In many cases, the mechanisms of resistance 
are associated in the same strains, therefore, resistance 
should be surveyed using patterns of resistance (i.e. 
susceptibility or resistance to several drugs taken 
together) rather than resistance to each drug taken 
separately. 
CONCLUSION 
Continued surveillance of antibacterial susceptibility 
patterns is an integral part of monitoring the 
development of resistance. Since resistance develops 
over a period of time, surveillance must be maintained 
to detect trends [89]. When used appropriately by 
physicians, health administrators and the commercial 
pharmaceutical industry, surveillance data can offer 
economic as well as health benefits to health care 
systems [90]. 
Within each hospital, continual surveillance of 
prevalent strains and their resistance patterns is 
fundamental as a means of establishing the significance 
of resistance in clinical infection and in determination 
of hospital prescribing policies [91]. There is also a 
need for national data to assist the formulation of 
policies for the supply and use of antibacterial agents 
in man and animals and to encourage responsible 
action by manufacturers in the promotion of their 
products [34]. As newer agents take the place of older 
ones, rational prescribing of existing drugs is needed. 
This may be obtained through education and with the 
application of national and supranational networks of 
surveillance, which will anticipate trends in resistance. 
DISCUSSION 
Prof. F. Baquero: By prescribing a ureido penicillin 
rather than third-generation cephalosporins or 
prescribing fourth-generation cephalosporins rather than 
carbapenems, could the development of resistance be 
avoided? Also, by switching the prescriptions every 
two or three months, changng the predominantly 
used antibiotic within a hospital or ICU, could the 
selection of resistance within one unit or hospital be 
prevented, whilst avoiding contamination of the whole 
hospital with resistant organisms? 
Dr. A. Voss: There are data regarding the switching 
of aminoglycosides in order to stop resistance 
development, however, to my knowledge, there are 
no data regarding the switching of P-lactams, in order 
to prevent resistance development. 
Prof. B. Wiedemann: The incidence of ESBL 
producing strains among Enterobactenaceae mentioned 
is in the range 1-30%, using data taken from specific 
surveys. However, in some surveys the incidence of 
ESBLs among E .  coli is < 1%. The figures could reflect 
outbreaks in certain hospitals which may increase the 
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incidence and, therefore, a figure of 1-30% may be an 
overestimate. 
Dr. R. Spencer: This figure is a range and not an 
average, and may include high figures &om an outbreak 
from a single collecting center. 
Prof. B. Wiedemann: The real incidence of ESBL 
producing strains in Germany is < 1%, according to 
data from the Paul Ehrlich Society survey, therefore the 
range 1-30% gives the impression of a high percentage, 
but in fact the rate could be much lower. 
Dr. R. Spencer: Is there a reference €or the < 1% figure 
in Germany? 
Prof. B. Wiedemann: There is no specific data 
indicating whether  the  strains which  were  
ceftazidime-resistant were all ESBL producing. There 
is an indication that very few strains were ESBL 
producing (derivatives of TEM and SHV). 
Prof. A. Bauenfeind: An average number of incidence 
is not a useful figure for infections by ESBL-producers 
which are typically outbreaks restricted to specific 
intensive care units. 
Prof. B. Wiedemann: In the studies conducted by 
the Paul Ehrlich Society, there has been little change 
in the incidence of resistance for many years. More 
recently, there has been a permanent increase in 
ampicillin resistance among E. coli. The rate has increased 
from 25-32% in 1986 to current levels of 37%. There 
has also been a steady increase in aminoglycoside 
resistance among S. aureus. This sudden increase in 
resistance is a cause for concern. 
Dr. R. Spencer: Are there any suggestions as to why 
this has happened? 
Prof. B. Wiedemann: Some possible explanations 
for an increase in resistance, could be that the patients 
are older, more patients are seriously ill and 
consequently there are more infections. In Germany, 
life expectancy is increasing and one third of all 
infections are in patients > 65 years, resulting in an 
increase in the use of antibiotics by 5% per year. 
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